HeartBeam Inc. Strengthens Cardiac Care Innovation with New Patents
HeartBeam Inc. has secured two new U.S. patents for its 3D ECG and cardiac monitoring technology, marking a significant advancement in remote cardiac diagnostics and enhancing the company's intellectual property portfolio.
HeartBeam Inc. (NASDAQ: BEAT) has recently been issued two new U.S. patents, further cementing its role in the innovation of cardiac care technologies. These patents cover the company's compact, cable-free 3D ECG device and a rhythm analysis algorithm designed to identify arrhythmias through continuous signal input. This development is pivotal as it enhances HeartBeam's ability to provide remote cardiac diagnostics, a growing need in today's healthcare landscape.
The 3D ECG device utilizes chest and finger electrodes to gather high-fidelity signals in three non-coplanar directions, enabling on-demand symptom recording and 12-lead ECG synthesis. Currently under FDA review, the device's software is supported by data from the VALID-ECG pivotal study, indicating its potential to revolutionize how cardiac conditions are monitored and diagnosed outside traditional medical facilities.
With these new patents, HeartBeam now holds a total of 20 issued patents and has 34 additional filings, showcasing its commitment to leading the digital cardiac care sector. The company's future plans include integrating AI capabilities to further improve diagnostic accuracy, promising a new era of precision in cardiac health management. This advancement not only benefits patients by facilitating early detection and treatment of cardiac conditions but also positions HeartBeam as a key player in the medical technology industry.